search
Back to results

Intramyocardial Haemorrhage in Patients With Primary STEMI (HaemInCor)

Primary Purpose

Myocardial Infarction, STEMI, Myocardial Necrosis

Status
Completed
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
Pharmaco-invasive strategy
Primary PCI
Sponsored by
Tomsk National Research Medical Center of the Russian Academy of Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Myocardial Infarction focused on measuring Intramyocardial haemorrhage, Myocardial Infarction, ST Elevation Myocardial Infarction, Primary Percutaneous Coronary Intervention, Pharmaco invasive strategy, Fibrinolytic therapy, Global longitudinal strain, Myocardial Necrosis, Coronary Artery Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years at time of randomization (18 years and older);
  • Acute myocardial infarction;
  • Reperfusion of the infarct-related coronary artery in terms within 12 h of symptom onset;
  • Written the informed consent to participate in research;

Exclusion Criteria:

  • Inability to obtain informed consent;
  • Patients previously undergone endovascular / surgical revascularization of coronary artery;
  • Severe comorbidity;
  • History of myocardial infarction;
  • History of intracranial haemorrhage;
  • Pulmonary edema, cardiogenic shock;
  • Creatinine clearance <30 mL/min or dialysis;
  • Unable to undergo or contra-indications for MRI;
  • Allergy for contrast agent;
  • Indication or use of oral anticoagulant therapy;
  • Major bleedind;
  • Atrio-ventricular block II and III degree;
  • Active gastroduodenal ulcer;
  • Aortic dissection;
  • Acute psychotic disorders

Sites / Locations

  • Cardiology Research Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Pharmaco-invasive strategy

Primary PCI

Arm Description

Fibrinolytic therapy (Streptokinase, Alteplasa, Tenecteplasa in standard dose) is conducted within 12 h of symptom onset in the pre-hospital setting if primary PCI cannot be performed within 120 min from STEMI diagnosis. Then PCI is performed to all of patients.

Primary percutaneous coronary intervention (PCI) in patients with primary STEMI

Outcomes

Primary Outcome Measures

Intramyocardial haemorrhage in primary STEMI measure
Intramyocardial haemorrhage (%) in patients with primary STEMI as assessed by cardiac magnetic resonance imaging 2 days after reperfusion

Secondary Outcome Measures

Left ventricular ejection fraction (LVEF) recovery measure
Left ventricular ejection fraction (LVEF) (%) recovery measured with echocardiography 7 days and 3 months after reperfusion strategies
Global Longitudinal Strain
Global Longitudinal Strain (%) measured with echocardiography 7 days and 3 months after reperfusion strategies
Recurrent myocardial infarction measure
Incidence of recurrent myocardial infarction (%) 3 months after STEMI
Heart failure incidence measure
Incidence of heart failure (%) 3 months after STEMI
Stroke incidence measure
Incidence of stroke (%) 3 months after STEMI
Mortality measure
Mortality rate (%) 3 months after STEMI
Major bleeding incidence measure
Incidence of major bleeding (%) 3 months after STEMI

Full Information

First Posted
September 17, 2018
Last Updated
April 4, 2019
Sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT03677466
Brief Title
Intramyocardial Haemorrhage in Patients With Primary STEMI
Acronym
HaemInCor
Official Title
Clinical Trial Appreciating Intramyocardial Haemorrhage in Patients With Primary STEMI and Different Reperfusion Strategies (Pharmaco Invasive Strategy and Primary PCI)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
January 25, 2018 (Actual)
Primary Completion Date
October 30, 2018 (Actual)
Study Completion Date
March 20, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to assess the frequency and intensity of intramyocardial haemorrhage in patients with primary STEMI and different reperfusion strategies.
Detailed Description
The study non-randomized, opened, controlled. In half of patients despite on carried in-time reperfusion therapy intramyocardial haemorrhage determined after a long-term period of severe ischemia. Earlier, definition of intramyocardial haemorrhage was possible only by autopsy. Nowaday, cardiac contrast MRI is the best diagnostic method, which allows to assess the regional and global function of the LV, structural changes in myocardial tissue and also in T2 mode it became assessable to reveal intramyocardial haemorrhage. Taking into account the results of previous researches, it can be concluded that the intramyocardial haemorrhage was determined in half of patients with primary PCI [1]. An influence of fibrinolytic therapy to the intramyocardial haemorrhage was conducted in small group of patients in one trial, and therefore further data will be actual and useful [2]. It is planned to study 60 patients with primary STEMI using standard therapy. The patients will be divided into 2 groups. Patients of the 1st group will be treated by pharmaco-invasive strategy. The 2nd group will be treated by primary PCI. Patients in all groups after reperfusion strategies will be conducted cardiac contrast MRI for detection intramyocardial haemorrhage within 2 days onset. At day 7 and through 3 months, the clinical condition of the patients will be assessed and cardiac ultrasound will be performed for the evaluation of myocardial contractile function and 2D global longitudinal strain. Also, the incidence rate of secondary endpoints will be evaluated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction, STEMI, Myocardial Necrosis, Myocardial Injury
Keywords
Intramyocardial haemorrhage, Myocardial Infarction, ST Elevation Myocardial Infarction, Primary Percutaneous Coronary Intervention, Pharmaco invasive strategy, Fibrinolytic therapy, Global longitudinal strain, Myocardial Necrosis, Coronary Artery Disease

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pharmaco-invasive strategy
Arm Type
Experimental
Arm Description
Fibrinolytic therapy (Streptokinase, Alteplasa, Tenecteplasa in standard dose) is conducted within 12 h of symptom onset in the pre-hospital setting if primary PCI cannot be performed within 120 min from STEMI diagnosis. Then PCI is performed to all of patients.
Arm Title
Primary PCI
Arm Type
Active Comparator
Arm Description
Primary percutaneous coronary intervention (PCI) in patients with primary STEMI
Intervention Type
Drug
Intervention Name(s)
Pharmaco-invasive strategy
Other Intervention Name(s)
Metalyse, Actilyse, Tenecteplase, Alteplase, Streptokinase
Intervention Description
Patient with primary STEMI will received standard doses of fibrinolytics with following PCI. After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography.
Intervention Type
Procedure
Intervention Name(s)
Primary PCI
Intervention Description
After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
Primary Outcome Measure Information:
Title
Intramyocardial haemorrhage in primary STEMI measure
Description
Intramyocardial haemorrhage (%) in patients with primary STEMI as assessed by cardiac magnetic resonance imaging 2 days after reperfusion
Time Frame
2 days
Secondary Outcome Measure Information:
Title
Left ventricular ejection fraction (LVEF) recovery measure
Description
Left ventricular ejection fraction (LVEF) (%) recovery measured with echocardiography 7 days and 3 months after reperfusion strategies
Time Frame
3 months (with intermediate measurement at day 7 after reperfusion)
Title
Global Longitudinal Strain
Description
Global Longitudinal Strain (%) measured with echocardiography 7 days and 3 months after reperfusion strategies
Time Frame
3 months (with intermediate measurement at day 7 after reperfusion)
Title
Recurrent myocardial infarction measure
Description
Incidence of recurrent myocardial infarction (%) 3 months after STEMI
Time Frame
3 months
Title
Heart failure incidence measure
Description
Incidence of heart failure (%) 3 months after STEMI
Time Frame
3 months
Title
Stroke incidence measure
Description
Incidence of stroke (%) 3 months after STEMI
Time Frame
3 months
Title
Mortality measure
Description
Mortality rate (%) 3 months after STEMI
Time Frame
3 months
Title
Major bleeding incidence measure
Description
Incidence of major bleeding (%) 3 months after STEMI
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years at time of randomization (18 years and older); Acute myocardial infarction; Reperfusion of the infarct-related coronary artery in terms within 12 h of symptom onset; Written the informed consent to participate in research; Exclusion Criteria: Inability to obtain informed consent; Patients previously undergone endovascular / surgical revascularization of coronary artery; Severe comorbidity; History of myocardial infarction; History of intracranial haemorrhage; Pulmonary edema, cardiogenic shock; Creatinine clearance <30 mL/min or dialysis; Unable to undergo or contra-indications for MRI; Allergy for contrast agent; Indication or use of oral anticoagulant therapy; Major bleedind; Atrio-ventricular block II and III degree; Active gastroduodenal ulcer; Aortic dissection; Acute psychotic disorders
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Evgeny V. Vyshlov
Organizational Affiliation
Tomsk NRMC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cardiology Research Institute
City
Tomsk
ZIP/Postal Code
634012
Country
Russian Federation

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25212800
Citation
Hamirani YS, Wong A, Kramer CM, Salerno M. Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2014 Sep;7(9):940-52. doi: 10.1016/j.jcmg.2014.06.012.
Results Reference
result
PubMed Identifier
26763281
Citation
Carrick D, Haig C, Ahmed N, McEntegart M, Petrie MC, Eteiba H, Hood S, Watkins S, Lindsay MM, Davie A, Mahrous A, Mordi I, Rauhalammi S, Sattar N, Welsh P, Radjenovic A, Ford I, Oldroyd KG, Berry C. Myocardial Hemorrhage After Acute Reperfused ST-Segment-Elevation Myocardial Infarction: Relation to Microvascular Obstruction and Prognostic Significance. Circ Cardiovasc Imaging. 2016 Jan;9(1):e004148. doi: 10.1161/CIRCIMAGING.115.004148.
Results Reference
result

Learn more about this trial

Intramyocardial Haemorrhage in Patients With Primary STEMI

We'll reach out to this number within 24 hrs